In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Late Breaking Science in Cardiovascular Pharmacology
Session

Event : ESC Congress 2019

Topic : Pharmacology and Pharmacotherapy

  • Session type : Late-Breaking Science
  • Date : 31 August 2019
  • Time : 13:00 - 14:25

5 presentations in this session

International Registry of Anakinra for Pericarditis

Event : ESC Congress 2019

  • Session : Late Breaking Science in Cardiovascular Pharmacology
  • Speaker : M Imazio (Torino,IT)

A risk based approach to the role of aspirin on cardiovascular risk reduction in a healthy older cohort

Event : ESC Congress 2019

  • Session : Late Breaking Science in Cardiovascular Pharmacology
  • Speaker : C Reid (Perth,AU)

Relationship between hypoglycaemia, outcomes and empagliflozin treatment effect in EMPA-REG OUTCOME

Event : ESC Congress 2019

  • Session : Late Breaking Science in Cardiovascular Pharmacology
  • Speaker : D Fitchett (Toronto,CA)

Effects of omega-3 fatty acid supplements on arrhythmias in the ASCEND study

Event : ESC Congress 2019

  • Session : Late Breaking Science in Cardiovascular Pharmacology
  • Speaker : S Parish (Oxford,GB)

Combination of low dose rivaroxaban and aspirin in females and males with chronic coronary artery disease or peripheral artery disease

Event : ESC Congress 2019

  • Session : Late Breaking Science in Cardiovascular Pharmacology
  • Speaker : Y Liang (Beijing,CN)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are